Arcutis Biotherapeutics annual operating margin
2022
2023
2024
2025
Arcutis Biotherapeutics's operating margin was −3.29% for fiscal 2025.
View full Arcutis Biotherapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −3.29% | +73.81 pp |
| 2024 | 2024-12-31 | −77.10% | +748.99 pp |
| 2023 | 2023-12-31 | −826.08% | +7356.96 pp |
| 2022 | 2022-12-31 | −8,183.04% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 12.65% | +30.58 pp |
| Q1 2026 | 2026-03-31 | −8.62% | +29.80 pp |
| Q4 2025 | 2025-12-31 | 14.42% | +25.42 pp |
| Q3 2025 | 2025-09-30 | 8.59% | +95.88 pp |
| Q2 2025 | 2025-06-30 | −17.93% | +144.36 pp |
| Q1 2025 | 2025-03-31 | −38.42% | +108.19 pp |
| Q4 2024 | 2024-12-31 | −11.00% | +441.23 pp |
| Q3 2024 | 2024-09-30 | −87.29% | +367.81 pp |
| Q2 2024 | 2024-06-30 | −162.28% | +1237.36 pp |
| Q1 2024 | 2024-03-31 | −146.61% | +2595.75 pp |
| Q4 2023 | 2023-12-31 | −452.23% | +1858.61 pp |
| Q3 2023 | 2023-09-30 | −455.10% | +13992.90 pp |
| Q2 2023 | 2023-06-30 | −1,399.64% | — |
| Q1 2023 | 2023-03-31 | −2,742.36% | — |
| Q4 2022 | 2022-12-31 | −2,310.84% | — |
| Q3 2022 | 2022-09-30 | −14,448.00% | — |
Across the available reported history, Arcutis Biotherapeutics's operating margin increased from −77.10% to −3.29%, a change of +73.81 percentage points. The latest reported quarter, Q2 2026, shows 12.65%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcutis Biotherapeutics filings at SEC.gov ↗